Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States

References

• Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2014–2018. HIV surveillance supplemental report 2020;25(No. 1). [cited 2021 Oct 28]. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
   Google Scholar
• Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):185–191.
   PubMed Web of Science ®Google Scholar
• Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438–e447.
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
   PubMed Web of Science ®Google Scholar
• Farnham PG, Gopalappa C, Sansom SL, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64(2):183–189.
   PubMed Web of Science ®Google Scholar
• Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai project study group. N Engl J Med. 2000;342(13):921–929.
   PubMed Web of Science ®Google Scholar
• Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–181.
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379–1389.
   PubMed Web of Science ®Google Scholar
• Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral Society – USA panel. JAMA. 2020;324(16):1651–1669.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. [cited 2021 Oct 28]. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/what-start-initial-combination-regimens-antiretroviral-naive
   Google Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70(7):1267–1274.
   PubMed Web of Science ®Google Scholar
• Chen YW, Hardy H, Pericone CD, et al. Real-world assessment of weight change in people with HIV-1 after initiating integrase strand transfer inhibitors or protease inhibitors. J Health Econ Outcomes Res. 2020;7(2):102–110.
   PubMedGoogle Scholar
• Chow W, Donga P, Cote-Sergent A, et al. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus. Curr Med Res Opin. 2020;36(8):1313–1323.
   PubMed Web of Science ®Google Scholar
• Mounzer K, Brunet L, Hsu R, et al. Changes in BMI associated with antiretroviral regimens in treatment-experienced, virologically suppressed individuals living with HIV. Paper presented at: IDWeek2019; Washington, DC.
   Google Scholar
• Norwood J, Turner M, Bofill C, et al. Brief report: weight gain in persons with HIV switched from Efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–531.
   PubMed Web of Science ®Google Scholar
• Wu KS, Anderson C, Little SJ. Integrase strand transfer inhibitors play the main role in greater weight gain among men with acute and early HIV infection. Open Forum Infect Dis. 2021;8(1):ofaa619.
   PubMed Web of Science ®Google Scholar
• Koethe JR, Jenkins CA, Turner M, et al. Body mass index and the risk of incident noncommunicable diseases after starting antiretroviral therapy. HIV Med. 2015;16(1):67–72.
   PubMed Web of Science ®Google Scholar
• Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes. Front Endocrinol. 2018;9(705):705.
   PubMed Web of Science ®Google Scholar
• Achhra AC, Mocroft A, Reiss P, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016;17(4):255–268.
   PubMed Web of Science ®Google Scholar
• Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7(10):e666–e676.
   PubMed Web of Science ®Google Scholar
• Nozza S, Malagoli A, Maia L, et al. Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. J Antimicrob Chemother. 2017;72(10):2879–2886.
   PubMed Web of Science ®Google Scholar
• Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Dis. 2020;71(9):e471–e477.
   PubMed Web of Science ®Google Scholar
• Taylor BS, Liang Y, Garduno LS, et al. High risk of obesity and weight gain for HIV-infected uninsured minorities. J Acquir Immune Defic Syndr. 2014;65(2):e33–e40.
   PubMed Web of Science ®Google Scholar
• Orkin C, Elion R, Thompson M, et al. Changes in weight and BMI with first-line doravirine-based therapy. AIDS. 2021;35(1):91–99.
   PubMed Web of Science ®Google Scholar
• Leonard MA, Cindi Z, Bradford Y, et al. Efavirenz pharmacogenetics and weight gain following switch to integrase inhibitor-containing regimens. Clin Infect Dis. 2021;73(7):e2153–e2163.
   PubMed Web of Science ®Google Scholar
• Gomez M, Seybold U, Roider J, et al. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. Infection. 2019;47(1):95–102.
   PubMed Web of Science ®Google Scholar
• Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–815.
   PubMed Web of Science ®Google Scholar
• Emond B, Rossi C, Côté-Sergent A, et al. Weight change and predictors of weight change among patients initiated on darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide: a real-world retrospective study. J Health Econ Outcomes Res. 2021;8(1):88–98.
   PubMedGoogle Scholar
• Janssen Pharmaceuticals. Symtuza – Prescribing Information. 2018 [cited 2018 Apr 27]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SYMTUZA-pi.pdf
   Google Scholar
• Gilead Sciences. Biktarvy – Prescribing Information. 2018 [cited 2018 Apr 26]. Available from: https://www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf
   Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–3107.
   PubMed Web of Science ®Google Scholar
• Altice F, Evuarherhe O, Shina S, et al. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. PPA. 2019;13:475–490.
   Web of Science ®Google Scholar
• Clay PG, Yuet WC, Moecklinghoff CH, et al. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15(1):17.
   PubMed Web of Science ®Google Scholar
• Sutton SS, Hardin JW, Bramley TJ, et al. Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks. Am J Manag Care. 2016;22(4):242–248.
   PubMed Web of Science ®Google Scholar
• Bourgi K, Jenkins CA, Rebeiro PF, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020;23(4):e25484.
   PubMed Web of Science ®Google Scholar
• Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2020;33(1):10–19.
   PubMed Web of Science ®Google Scholar
• Shah S, Hindley L, Hill A. Are new antiretroviral treatments increasing the risk of weight gain? Drugs. 2021;81(3):299–315.
   PubMed Web of Science ®Google Scholar
• Lagathu C, Bereziat V, Gorwood J, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019;18(9):829–840.
   PubMed Web of Science ®Google Scholar
• Godfrey C, Bremer A, Alba D, et al. Obesity and fat metabolism in human immunodeficiency virus-infected individuals: immunopathogenic mechanisms and clinical implications. J Infect Dis. 2019;220(3):420–431.
   PubMed Web of Science ®Google Scholar
• Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS. 2003;17(Suppl 1):S141–S148.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093–2099.
   PubMed Web of Science ®Google Scholar
• Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001;50(6):1378–1388.
   PubMed Web of Science ®Google Scholar
• Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7(12):1327–1331.
   PubMed Web of Science ®Google Scholar
• Capel E, Auclair M, Caron-Debarle M, et al. Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes. Antivir Ther. 2012;17(3):549–556.
   PubMed Web of Science ®Google Scholar
• Dunn K, Gibson A, Van Landuyt E, et al. Low proportion of individuals develop metabolic syndrome (MetS) or hepatic fibrosis after switch to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed patients: a post hoc metabolic analysis. Paper presented at: International AIDS Society (IAS) Conference; 2021 Jul 18–21; virtual.
   Google Scholar
• Gorwood J, Bourgeois C, Pourcher V, et al. The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes. Clin Infect Dis. 2020;71(10):e549–e560.
   PubMed Web of Science ®Google Scholar
• Moure R, Domingo P, Gallego-Escuredo JM, et al. Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines. Antiviral Res. 2016;132:59–65.
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Borderi M, et al. Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients. J Antimicrob Chemother. 2019;74(3):731–738.
   PubMed Web of Science ®Google Scholar
• Dirajlal-Fargo S, Moser C, Brown TT, et al. Changes in insulin resistance after initiation of raltegravir or protease inhibitors with tenofovir-emtricitabine: AIDS clinical trials group A5260s. Open Forum Infect Dis. 2016;3(3):ofw174.
   PubMed Web of Science ®Google Scholar
• Domingo P, Villarroya F, Giralt M, et al. Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV. Int J Obes. 2020;44(9):1970–1973.
   Web of Science ®Google Scholar
• McMahon C, Trevaskis JL, Carter C, et al. Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight. PLoS One. 2020;15(2):e0229617.
   PubMed Web of Science ®Google Scholar
• Paisible AL, Chang CC, So-Armah KA, et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr. 2015;68(2):209–216.
   PubMed Web of Science ®Google Scholar
• Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–2512.
   PubMed Web of Science ®Google Scholar
• Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787–1797.
   PubMed Web of Science ®Google Scholar
• Bonnet F, Le Marec F, Leleux O, et al. Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort. BMC Infect Dis. 2020;20(1):850.
   PubMed Web of Science ®Google Scholar
• Isa SE, Oche AO, Kang’ombe AR, et al. Human immunodeficiency virus and risk of type 2 diabetes in a large adult cohort in Jos, Nigeria. Clin Infect Dis. 2016;63(6):830–835.
   PubMed Web of Science ®Google Scholar
• Herrin M, Tate JP, Akgun KM, et al. Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J Acquir Immune Defic Syndr. 2016;73(2):228–236.
   PubMed Web of Science ®Google Scholar
• Resnick HE, Valsania P, Halter JB, et al. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Community Health. 2000;54(8):596–602.
   PubMed Web of Science ®Google Scholar
• Luo J, Hodge A, Hendryx M, et al. BMI trajectory and subsequent risk of type 2 diabetes among middle-aged women. Nutr Metab Cardiovasc Dis. 2021;31(4):1063–1070.
   PubMed Web of Science ®Google Scholar
• Manfredi R. HIV infection and advanced age emerging epidemiological, clinical, and management issues. Ageing Res Rev. 2004;3(1):31–54.
   PubMed Web of Science ®Google Scholar
• Luther VP, Wilkin AM. HIV infection in older adults. Clin Geriatr Med. 2007;23(3):567–583, vii.
   PubMed Web of Science ®Google Scholar